Figure 7
From: Heparan sulfate mediates trastuzumab effect in breast cancer cells
HER2 and Syndecan-1 expression in MCF7 and MCF7-HPSE1 cells before and after trastuzumab treatment. These cells were treated for three days with 25 μg/mL of trastuzumab, fixed and prepared for confocal microscopy using the specific antibodies anti-HER2 stained with the secondary antibody Alexa Fluor® 488 (green) or anti-Syn-1 stained with the secondary antibody Alexa Fluor® 594 (red), as described in methods. (A) MCF7, (B) MCF7 treated with trastuzumab (25 μg/mL), (C) MCF7-HPSE1, (D) MCF7-HPSE1 treated with trastuzumab (25 μg/mL).